[{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"82b7c711-3e03-4142-888d-9fd32dafa3da","Styles":"page-break-before:always","Classes":"None","Text":"","ParentId":"662387c2-8541-4974-8802-500f57b4edc2"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"59b029c2-1fc3-40f0-a4a1-de0639addab1","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"e9df568b-8e84-4fc8-ad67-fa2f52a9aec1","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"31c5495d-6728-4171-8a90-0b98f478f337","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"4d5cb9de-a0b2-41b7-aff0-957d1229361b","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"f72b5279-4e7f-44ab-98b6-e84348af150d","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"94cd479b-8101-41bb-b0a5-8e739981dad2","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"4286f134-9efb-4e31-9576-30b361ea7771","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"29fd87d1-2b62-439d-a7ee-1fef0c049fe3","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"3246f919-fc0d-4723-8bb7-1dbb867add4c","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"618aea47-20fa-4a4b-9dbc-732c780d7384","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"037eed1d-7b2e-4c53-a560-2059141d437d","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"c400935e-8c5e-45cf-bf0c-ae563b00164a","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"1110fb31-6a9c-4c17-84ce-c26f731e1aa9","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"1409d917-e2c2-4d79-89d5-100503e8a112","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"b9e3778c-2a3d-4f0f-a404-1695072a235e","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"248395bf-c279-44ef-8480-f56f6d5bbddc","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"d8d13272-2c49-4de9-9879-92b7ff65673b","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"3187c861-c3e9-42d4-8686-43d31a495cb2","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"cb038d06-ce58-4554-ac5b-c7b2e70f85be","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"2483dfd0-853d-4e97-9b8b-ad4b3b8d3ad1","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"922de208-cf94-40c3-a4ae-7aa4007621ce","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"5222b7cf-fc9e-4288-95c8-91705f0671af","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"0e0d5664-a81c-46b0-8037-73a1d16b0b6f","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'> <\/span><\/p>","ID":"cbeb901d-6ba7-421c-ad50-84103eec02a0","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p align=\"center\" class=\"No-numheading3Agency\" style=\"margin:0in;text-align:center; page-break-after:auto\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; text-transform:uppercase'>Annex II<\/span><\/p>","ID":"17dfe449-2bd8-4c36-a95e-ce065b4a567b","Styles":"margin:0in;text-align:center;\npage-break-after:auto","Classes":"['No-numheading3Agency']","Text":"Annex II","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"4dd7341d-18a7-4d42-9360-1d1b21edcb6e","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE <\/span><\/b><\/p>","ID":"ea2c33f0-0a41-4b19-8016-e92f36b88101","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Text":"A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"d62a04ee-1f82-4c47-ac0a-dd9e3a7f4aca","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/b><\/p>","ID":"264ddfe7-6ea6-476e-8c4b-a406967d8adc","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Text":"B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"TitleB\"><span lang=\"EN-GB\" style=\"text-transform:none\"> <\/span><\/p>","ID":"46232130-049e-4518-931e-bf1f633649ba","Styles":"None","Classes":"['TitleB']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">C.      OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p>","ID":"e2ec619b-db44-4105-9113-019f0f6040d1","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Text":"C.      OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"TitleB\"><span lang=\"EN-GB\" style=\"text-transform:none;font-weight:normal\"> <\/span><\/p>","ID":"2596f037-6c94-4277-995b-a37ae77f4943","Styles":"None","Classes":"['TitleB']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/b><\/p>","ID":"64b51cf7-453c-4767-8b7c-272725962d85","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Text":"D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"34cb670d-e743-434e-8197-cdd023bdef10","Styles":"margin-left:28.35pt;text-indent:-28.35pt","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman Bold\"; text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"bd07cdc8-2ba9-4fb5-9253-578d6723239a","Styles":"None","Classes":"None","Text":"","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman Bold\"; text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"8f5ac241-5df2-45fc-8fcc-12b87b9cbc3b","Styles":"font-size:11.0pt;font-family:\"Times New Roman Bold\";\ntext-transform:uppercase","Classes":"None","Text":" ","ParentId":"bd07cdc8-2ba9-4fb5-9253-578d6723239a"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"e0b2cc36-623f-436e-90d1-481f8293c426","Styles":"page-break-before:always","Classes":"None","Text":"","ParentId":"8f5ac241-5df2-45fc-8fcc-12b87b9cbc3b"},{"Element":"<p class=\"TitleB\"><span lang=\"EN-GB\">A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE<\/span><\/p>","ID":"9d1cef09-23eb-479d-9f3a-9f6b592adbba","Styles":"None","Classes":"['TitleB']","Text":"A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"3c89da59-c50e-4e7a-8404-a89325979dd8","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Name and address of the manufacturer(s) responsible for batch release<\/span><\/u><\/p>","ID":"9c7c6f61-51b4-42b9-be31-a66c37d66cf3","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Name and address of the manufacturer(s) responsible for batch release","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"116e6d3d-0dd6-466b-b0b9-a45c7296959c","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Almac Pharma Services (Ireland) Limited<\/span><\/p>","ID":"53778883-e7d3-4e04-a359-395cbe9ac1d7","Styles":"None","Classes":"['MsoNormal']","Text":"Almac Pharma Services (Ireland) Limited","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Finnabair Industrial Estate<\/span><\/p>","ID":"92aebd58-9f73-48d9-b7c0-ef63d6301292","Styles":"None","Classes":"['MsoNormal']","Text":"Finnabair Industrial Estate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Dundalk<\/span><\/p>","ID":"70ebc927-0bcc-480d-ba91-c40ddc5023c1","Styles":"None","Classes":"['MsoNormal']","Text":"Dundalk","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Co. Louth<\/span><\/p>","ID":"ea20fe52-ce26-4c0d-a087-240e46eaace5","Styles":"None","Classes":"['MsoNormal']","Text":"Co. Louth","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">A91 P9KD<\/span><\/p>","ID":"d6a88fb1-ef8c-490a-a9af-4e7ff3e929e3","Styles":"None","Classes":"['MsoNormal']","Text":"A91 P9KD","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Ireland<\/span><\/p>","ID":"733e74f8-850e-43d2-b876-c7beb25d08a7","Styles":"None","Classes":"['MsoNormal']","Text":"Ireland","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"b3501f11-4192-4980-8f45-9d4054d231b4","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Almac Pharma Services Ltd.<\/span><\/p>","ID":"49c5c783-a40b-4672-b775-c8df53a89611","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Almac Pharma Services Ltd.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Seagoe Industrial Estate<\/span><\/p>","ID":"e5afd5bb-8eba-418d-88eb-16c497e11041","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Seagoe Industrial Estate","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Craigavon<\/span><\/p>","ID":"e55f3dd3-3060-4804-85ec-f060ef58dc5b","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Craigavon","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Co. Armagh BT63 5UA<\/span><\/p>","ID":"347bfa1e-afd8-4ebd-9ae2-79318aacca9a","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"Co. Armagh BT63 5UA","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">United Kingdom<\/span><\/p>","ID":"6b6eba26-c0ff-4081-af48-8a21ca6b70aa","Styles":"line-height:normal","Classes":"['MsoNormal']","Text":"United Kingdom","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"cb434b95-4f40-486e-b516-dc4c96356727","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.<\/span><\/p>","ID":"c0f381d6-7a8a-46f6-a8c0-04b56c512407","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":"The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p>","ID":"be90c820-6269-497c-ab96-693721e56463","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p>","ID":"7d83cc03-21b7-4b66-8e19-bb304b450a52","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"TitleB\"><span lang=\"EN-GB\">B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/p>","ID":"b6501253-82ff-49ba-9387-a9f1ecd1c0e8","Styles":"None","Classes":"['TitleB']","Text":"B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p>","ID":"76022e5e-5b02-41d1-a6ee-4a5dd170f533","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'>Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).<\/span><\/p>","ID":"0284a16f-ec2a-4e64-87d8-d28c03047b5a","Styles":"None","Classes":"['NormalAgency']","Text":"Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p>","ID":"9936a487-82df-4945-afbd-c89bd7019858","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"TitleB\"><span lang=\"EN-GB\">C.      Other conditions and requirements of the Marketing Authorisation<\/span><\/p>","ID":"6798122f-8953-4570-b80a-41a4c6137e96","Styles":"None","Classes":"['TitleB']","Text":"C.      Other conditions and requirements of the Marketing Authorisation","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"52cb555f-89a8-4e76-9bbe-f06d6eccad21","Styles":"None","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom: 0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\">Periodic safety update reports (PSURs)<\/span><\/b><\/p>","ID":"03cbe4ca-53de-4e52-bbd0-544f468a97f0","Styles":"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:\nnormal","Classes":"['MsoNormal']","Text":"\u00b7         Periodic safety update reports (PSURs)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\"> <\/span><\/p>","ID":"0d599bed-cedd-4beb-942c-1daf98c74cde","Styles":"margin-right:28.35pt;line-height:normal","Classes":"['MsoNormal']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-1.85pt;line-height:normal\"><span lang=\"EN-GB\">The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001\/83\/EC and any subsequent updates published on the European medicines web-portal.<\/span><\/p>","ID":"bcacf56b-9680-43c3-99a5-36ba3acfc1e1","Styles":"margin-right:-1.85pt;line-height:normal","Classes":"['MsoNormal']","Text":"The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001\/83\/EC and any subsequent updates published on the European medicines web-portal.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"e10a4a72-a839-4ce0-aef7-d10ba2860971","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p>","ID":"32f1d3a7-bb5c-4072-baf0-2b6193907089","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"TitleB\"><span lang=\"EN-GB\">D.      Conditions or restrictions with regard to the safe and effective use of the medicinal product<\/span><\/p>","ID":"590533f7-1f4c-483a-b496-2af6c4614e5c","Styles":"None","Classes":"['TitleB']","Text":"D.      Conditions or restrictions with regard to the safe and effective use of the medicinal product","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"d170fca3-1c66-46c1-beb9-72e00ea0cc67","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Risk management plan (RMP)<\/span><\/b><\/p>","ID":"9ef64c6c-452f-482c-af3f-545ec1f3a78e","Styles":"margin-left:.25in;text-indent:-.25in","Classes":"['NormalAgency']","Text":"\u00b7         Risk management plan (RMP)","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><u><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'><span style=\"text-decoration:none\"> <\/span><\/span><\/u><\/p>","ID":"f6b59d3c-92ba-42cb-af86-7d039551e38d","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.<\/span><\/p>","ID":"5923312a-cf0b-49d6-a1b1-d26eeb265f36","Styles":"margin-right:28.35pt;line-height:normal","Classes":"['MsoNormal']","Text":"The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"2c6089a6-5535-4aa5-b38e-4876b1979016","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><span lang=\"EN-GB\">An updated RMP should be submitted:<\/span><\/p>","ID":"f5fb7805-4374-40b5-a173-f97d8e7a9139","Styles":"margin-right:-.05pt;line-height:normal","Classes":"['MsoNormal']","Text":"An updated RMP should be submitted:","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom: 0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">At the request of the European Medicines Agency;<\/span><\/p>","ID":"f7be957b-67fc-4b7d-b04f-bb27d291e49e","Styles":"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:\nnormal","Classes":"['MsoNormal']","Text":"\u00b7         At the request of the European Medicines Agency;","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom: 0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height: normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><span lang=\"EN-GB\">Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit\/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.<\/span><\/p>","ID":"c843186c-cc87-445b-961e-8694da9f46e2","Styles":"margin-top:0in;margin-right:-.05pt;margin-bottom:\n0in;margin-left:.25in;margin-bottom:.0001pt;text-indent:-.25in;line-height:\nnormal","Classes":"['MsoNormal']","Text":"\u00b7         Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit\/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> <\/span><\/p>","ID":"dfa48662-1ca3-4e87-8c8f-a1b3666c717d","Styles":"margin-bottom:0in;line-height:normal","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\" style=\"margin-left:.25in;text-indent:-.25in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;font-family:Symbol\">\u00b7<span style='font:7.0pt \"Times New Roman\"'>         <\/span><\/span><b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Obligation to conduct post-authorisation measures<\/span><\/b><\/p>","ID":"b60b1d33-aa13-4495-b393-3a7f0e0a9e01","Styles":"margin-left:.25in;text-indent:-.25in","Classes":"['NormalAgency']","Text":"\u00b7         Obligation to conduct post-authorisation measures","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif; layout-grid-mode:line'> <\/span><\/p>","ID":"732a02cb-fd21-402f-a69a-4999eb6ee869","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif; layout-grid-mode:line'>The MAH shall complete, within the stated timeframe, the below measures:<\/span><\/p>","ID":"11c963d1-e00d-4293-8444-22756dff4147","Styles":"margin-bottom:0in;line-height:normal;page-break-after:\navoid","Classes":"['BodytextAgency']","Text":"The MAH shall complete, within the stated timeframe, the below measures:","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;page-break-after: avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif; layout-grid-mode:line'> <\/span><\/p>","ID":"149ac008-7b17-40a2-82ab-6ff133b3e04a","Styles":"margin-bottom:0in;line-height:normal;page-break-after:\navoid","Classes":"['BodytextAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"TableGrid1\" style=\"border-collapse:  collapse;border:none\"> <tr> <td style=\"width:3.75in;border:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"360\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;   font-family:\"Times New Roman\",serif;layout-grid-mode:line'>Description<\/span><\/b><\/p> <\/td> <td style=\"width:189.65pt;border:solid windowtext 1.0pt;   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal;   page-break-after:avoid\"><b><span lang=\"EN-GB\" style='font-size:11.0pt;   font-family:\"Times New Roman\",serif;layout-grid-mode:line'>Due date<\/span><\/b><\/p> <\/td> <\/tr> <tr> <td style=\"width:3.75in;border:solid windowtext 1.0pt;   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"360\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Long-term effectiveness study to compare disease progression among   children with CF who have a specified CFTR gating mutation and are aged 2   through 5 years at the time of Kalydeco treatment initiation versus disease progression   among concurrent matched cohort of children with CF who have never received   Kalydeco treatment.<\/span><\/p> <\/td> <td style=\"width:189.65pt;border-top:none;border-left:   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"253\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\">Interim analysis 1: December 2017<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\">Interim analysis 2: December 2019<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Interim analysis 3: December 2021<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\"> <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Final report: December 2023<\/span><\/p> <\/td> <\/tr> <\/table>","ID":"614b7537-f08d-43ce-bc24-2e49a72bcdc0","Styles":"border-collapse:\n collapse;border:none","Classes":"['TableGrid1']","Text":"   Description   Due date     Long-term effectiveness study to compare disease progression among   children with CF who have a specified CFTR gating mutation and are aged 2   through 5 years at the time of Kalydeco treatment initiation versus disease progression   among concurrent matched cohort of children with CF who have never received   Kalydeco treatment.   Interim analysis 1: December 2017   Interim analysis 2: December 2019   Interim analysis 3: December 2021   Final report: December 2023   ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<p class=\"NormalAgency\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family: \"Times New Roman\",serif'> <\/span><\/p>","ID":"0ed69f8a-68e7-40d6-b90f-f4b9313c2227","Styles":"None","Classes":"['NormalAgency']","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"448e32c5-153c-4314-b42b-13e4e8b8c266","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Text":" ","ParentId":"41a55993-df84-4176-b094-22b5447b9115"}]